<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611867</url>
  </required_header>
  <id_info>
    <org_study_id>AA2058</org_study_id>
    <nct_id>NCT04611867</nct_id>
  </id_info>
  <brief_title>Study of PRO in Patients With Advanced Pancreatic or Lung Cancer (BetterEveryDay)</brief_title>
  <acronym>BetterEveryDay</acronym>
  <official_title>Study of Supportive Application With Integrated Patient-Reported Outcomes in Patients With Advanced Pancreatic or Lung Cancer (BetterEveryDay)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inna Chen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic and lung cancer are ones of the leading causes of cancer-related deaths. During&#xD;
      the course of illness, these patients often experience marked physical suffering,&#xD;
      psychological distress and frequent unplanned resource-demanding hospitalized care. Patients&#xD;
      with pancreatic and lung cancer have highest rates of unplanned hospitalizations.&#xD;
      Investigator initiated prospective &quot;Study of Supportive Application with Integrated&#xD;
      Patient-Reported Outcomes in Patients with Advanced Pancreatic or Lung Cancer&#xD;
      (BetterEveryDay)&quot; is to be initiated based on the great need for optimizing treatment care,&#xD;
      reducing hospitalizations and improving outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as an investigator initiated prospective study of patients with&#xD;
      advanced pancreatic and lung (non-small cell lung cancer, NSCLC) cancer initiating systemic&#xD;
      treatment to determine the feasibility and efficacy of supportive application with integrated&#xD;
      weekly Patient-Reported Outcomes (PRO) on unplanned hospitalization, Quality of Life (QoL),&#xD;
      survival, satisfaction with oncologist communication, and resource utilization.&#xD;
&#xD;
      This study will consist of Part A (Feasibility), as well as a possible Part B (Randomized&#xD;
      controlled trial, RCT).&#xD;
&#xD;
      Initially, 30 patients with advanced lung (NSCLC) and pancreatic cancer initiating systemic&#xD;
      therapy will be enrolled in the Part A to assess the feasibility of the supportive&#xD;
      application with integrated weekly PRO. Patients included in feasibility Part A will be&#xD;
      instructed in self-reporting via web-based supportive application with integrated weekly PRO.&#xD;
&#xD;
      In case of successfully completed Part A, the randomized Part B will be activated to&#xD;
      determine the efficacy of the supportive application with integrated weekly PRO on unplanned&#xD;
      hospitalization, QoL, survival, satisfaction and resource utilization for patients with&#xD;
      advanced lung (NSCLC) and pancreatic cancer initiating systemic therapy. Format of that Part&#xD;
      B will be adjusted if indicated based on the feasibility responses seen in the 30 patients in&#xD;
      Part A. Patients will be randomized in Part B with a 1:1 ratio in a stratified manner&#xD;
      according to cancer type (lung cancer versus pancreatic cancer). If initiated, the data from&#xD;
      Part B: RCT will be analyzed separately and will not be pooled with Part A for the purpose of&#xD;
      statistical analysis.&#xD;
&#xD;
      Over the course of the study patients in both arms will be asked to complete questionnaires&#xD;
      about QoL at baseline and week 12 and 24. Additionally, patients in both arms are asked to&#xD;
      complete the modified Health Care Climate Questionnaire (HCCQ) at week 12 and 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility (Part A)</measure>
    <time_frame>3 months</time_frame>
    <description>- Proportion of enrolled patients responding to at least two consecutive questionnaires by 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization (Part B)</measure>
    <time_frame>6 months</time_frame>
    <description>- Hospitalization with any unplanned admission to the hospital and/or emergency department within the 24 weeks beginning from the day of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 global health status/QoL scale</measure>
    <time_frame>6 months</time_frame>
    <description>- Adjusted mean change from baseline in global health status/QoL score from the EORTC QLQ-C30 questionnaire at 12 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 functional scales and symptom scales/items</measure>
    <time_frame>6 months</time_frame>
    <description>- Adjusted mean change from baseline in functional and symptom scales from the EORTC QLQ-C30 questionnaire at 6, 12 and 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>- Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with oncologist communication at 12 and 24 weeks as measured by the modified Health Care Climate Questionnaire (HCCQ)</measure>
    <time_frame>6 months</time_frame>
    <description>- Adjusted mean in score from the modified HCCQ at 12 and 24 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Out-of-patient care and resource utilization</measure>
    <time_frame>6 months</time_frame>
    <description>- Time to first ER visit and/or hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Out-of-patient care and resource utilization</measure>
    <time_frame>6 months</time_frame>
    <description>- Rates of hospital admissions</description>
  </other_outcome>
  <other_outcome>
    <measure>Out-of-patient care and resource utilization</measure>
    <time_frame>6 months</time_frame>
    <description>- Mean length of hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Out-of-patient care and resource utilization</measure>
    <time_frame>6 months</time_frame>
    <description>- Number of additional/unplanned nursing calls</description>
  </other_outcome>
  <other_outcome>
    <measure>Out-of-patient care and resource utilization</measure>
    <time_frame>6 months</time_frame>
    <description>- Number of additional/unplanned out-patient care visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolerability of systemic therapy</measure>
    <time_frame>6 months</time_frame>
    <description>- Time receiving active cancer treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention will be comprised of providing patients with supportive application with integrated PRO consisting of:&#xD;
Weekly self-reporting of PRO-CTCAE with integrated preparation questionnaire available for staff&#xD;
Daily monitoring of self-reporting by study staff&#xD;
Intervention if required based on self-reporting&#xD;
Reports to oncologists (at consultation)&#xD;
Information module about treatment, side effects and contact information</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care for patients will be included in no-intervention arm will consist of the standard procedures at Herlev Hospital, Department of Oncology for monitoring and documenting symptoms, which will be typical of oncology practice. Symptoms will be discussed and documented in the medical record during clinical encounters between patients and their oncologists. Patients will be encouraged to initiate telephone contact between visits for concerning symptoms, i.e. &quot;call early and often&quot;.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive application with integrated weekly PRO</intervention_name>
    <description>Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (aged 18 and over)&#xD;
&#xD;
          -  Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer&#xD;
&#xD;
          -  Written informed consent before any study procedures&#xD;
&#xD;
          -  Planning to receive 1st line systemic anticancer therapy within â‰¤2 weeks&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Access to the internet&#xD;
&#xD;
          -  Ability to read and respond to questions or able to complete questions with minimal&#xD;
             assistance required from an interpreter or family member&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No mobile device&#xD;
&#xD;
          -  Exhibiting signs of overt psychopathology or cognitive dysfunction&#xD;
&#xD;
          -  Any medical condition that the Investigator considers significant to compromise the&#xD;
             safety of the patient or that impairs the interpretation of study assessments&#xD;
&#xD;
          -  Patient participating in another interventional study during the surveillance period.&#xD;
             This is only relevant for studies that might interfere with the intervention.&#xD;
             Participation in protocols related only to treatment will not preclude participation&#xD;
             in the present study. Cases of doubt will be settled by the protocol responsible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inna M Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev and Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inna M Chen, MD</last_name>
    <phone>+45 38682898</phone>
    <email>Inna.Chen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev &amp; Gentofte University Hospital, Denmark</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Chen, MD</last_name>
      <phone>+45 38682898</phone>
      <email>Inna.Chen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Dorte Nielsen, MD DMSc</last_name>
      <phone>+45 38682344</phone>
      <email>Dorte.Nielsen.01@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inna Chen, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

